Defect of branched-chain amino acid metabolism promotes the development of Alzheimer’s disease by targeting the mTOR signaling

Huajie Li1,2, Dan Ye1,2, Wei Xie1,2, Fei Hua2,3, Yilin Yang2,4, Jian Wu1,2, Aifang Gu1,2, Yi Ren1,2 and Keshi Mao1,2

1Department of Neurology, the First People’s Hospital of Chang Zhou, Jiang Su, China; 2The Third Affiliated Hospital of Soochow University; 3Department of Endocrinology, the First People’s Hospital of Chang Zhou, Jiang Su, China; 4Department of Neurosurgery, the First People’s Hospital of Chang Zhou, Jiang Su, China

Correspondence: Huajie Li (lihuajie0589@sohu.com)

Introduction

Alzheimer’s disease (AD) is one of the most prevalent causes of dementia. Amyloid β42 and phosphorylated Tau proteins are established as core cerebrospinal biomarkers for AD [1]. However, treatment strategies targeted at reducing amyloids have failed to reverse cognitive symptoms. Cognitive decline is the result of complex pathophysiology and targeting amyloid-alone may not be sufficient to treat AD [2,3]. Instead, a broad outlook on neural-circuit-damaging processes may yield insights into new therapeutic strategies for curing memory loss in the disease.

AD is fundamentally a metabolic disease with molecular and biochemical features that correspond with diabetes and other peripheral insulin resistance disorders [4]. Advanced glycation end products generated by chronic hyperglycemia and their receptor for advanced glycation end products (RAGE) provide critical links between diabetes and AD [5]. Continued elucidation of the links between metabolic disorders and neural dysfunction promises to foster the development of effective therapeutic strategies [6]. However, diabetes is connected to AD clinically, and experimental molecular and biochemical links are limited. One of the evidence for connecting diabetes and AD is the signaling factor mammalian target of rapamycin (mTOR). mTOR was already well known as a regulator of growth and protein translation.
it is now clear that mTOR functions as a central coordinator of organismal metabolism in response to both environmental and hormonal signals, and it involved in the development of diabetes [7]. Interestingly, vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease [8]. mTOR is core regulator and effector of insulin signaling. Our prior work indicates that insulin degrading enzyme (IDE) contributes to the pathology in a mixed model of type 2 diabetes and AD [9], and that adenosine 3,5'-cyclic monophosphate/protein kinase A (cAMP/PKA) signaling pathway contributes to neuronal apoptosis via regulating IDE expression in a mixed model of type 2 diabetes and AD [10]. In addition, we showed that glucagon-like peptide 1 (GLP-1) receptor regulates cell growth through regulating IDE expression level in Aβ1-42-treated PC12 cells [11]. However, the mechanism connecting diabetes and AD is still not fully understood.

 Branched-chain amino acids (BCAAs, namely leucine, isoleucine, and valine) are amino acids having aliphatic side chains with a branch (a central carbon atom bound to three or more carbon atoms). The first step in the metabolism of BCAAs in most peripheral tissues, except the liver, is catalyzed by the cytosol or mitochondrial isofrom of branched-chain amino acid transaminase (BCAT1 and BCAT2). After BCAT, the next step in the BCAA metabolic pathway is rate controlling and the first irreversible step in BCAA metabolism [12]. BCAAs are recently reported to be associated with human diseases including cancer [13,14], diabetes [15,16], and cardiovascular diseases [17,18]. The use of high-throughput metabolomics allowed us to uncover the associations between the concentrations of BCAAs in blood and predisposition to diabetes and insulin resistance in human [15,19]. However, the functions of BCAAs and their metabolic enzymes in human neurons and AD remain unknown.

 Here, in the present work, we showed that BCAAs are tightly associated with diabetes and AD. The plasma levels of BCAAs were significantly increased in human diabetic AD patients as well as old individuals. Supplement of BCAAs in diet promoted the cognitive deficits in 3xTg-AD mice. BCAA accumulation may be due to the down-regulation of Bcat1 in the brains. Bcat1 down-regulation led to leucine accumulation, which promoted the phosphorylation of Tau protein in an mTOR-dependent manner.

Materials and methods

Patients

Diabetic and AD patients, as well as young and old healthy donors, were recruited at the First People's Hospital of Changzho. A written form of consent was obtained from all patients and donors. Blood samples were collected from the patients and donors and stored at −80°C before use. The study was approved by the clinical research ethics committee of the First People's Hospital of Changzho.

Mice

The triple transgenic Alzheimer disease (3xTg-AD) mice (Stock number 34830) were purchased from Jackson Lab. Aged (24-month-old) and db/db diabetic mice were purchased from Charles River Laboratories. Animals were given unrestricted access to a standard diet (4.3 kcal % fat, 18.8 kcal % protein, and 76.9 kcal % carbohydrate) and tap water. For wild-type and 3xTg-AD, mice were randomly assigned to control and BCAA-supplemented groups (1.5 mg/g body weight/day) in drinking water. BCAA supplementation was performed from 3-month-old for 3 months. For functional study, the behavior and memory defects of the animals were analyzed at 6 months. For Western blot and amyloid content analysis, the mice were killed and the brain tissues were subjected to protein extraction and Western blot or amyloid content measurement. The animal experiments were approved by the animal research ethics committee of the First People's Hospital of Changzho.

Neuron isolation and culture

Neurons were isolated from adult male wild-type or 3xTg AD mice using a Pierce Primary Neuron Isolation Kit (Thermo Fisher, 88280).

Measurement of BCAAs in the serum

The levels of BCAAs in the serum were measured as described previously [14], using liquid chromatography-tandem mass spectrometry (LC-MS/MS) at the Core Laboratory of Soochow University. Targeted LC-MS/MS was performed with standard valine, isoleucine, and leucine samples.

Western blot

Total proteins were extracted from brain tissues and neurons with RIPA buffer (Beyotime, P0013) supplied with proteinase inhibitor cocktail (Roche, 04693124001) and phosphatase inhibitor cocktail (Sigma, P5726). Total protein
(30 μg) was subjected to SDS-PAGE for protein separation. The proteins were transferred to PVDF membranes and blocked with 5% fat-free milk in TBST buffer, and then the membranes were incubated with individual primary antibodies overnight. Then the membranes were washed and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (Zhongshanjinqiao) for 2 h. Finally, the secondary antibodies were detected by SuperSignal™ Chemiluminescent HRP Substrates (Thermo Fisher, 32106). The following primary antibodies were used in the present study: anti-GAPDH antibody (Santa Cruz, sc-47724), anti-Bcat1 antibody (Novus Biological, NBP2-01826), anti-Tau antibody (Abcam, ab64193), anti-p-Tau antibody (Abcam, ab109390), anti-mTOR antibody (Cell Signaling Technology, 2983), anti-p-mTOR antibody (Cell Signaling Technology, 5536), anti-S6K1 antibody (Cell Signaling Technology, 9202), and anti-p-S6K1 antibody (Cell Signaling Technology, 9206).

**Quantitative real-time PCR**

Total RNAs were isolated from brain tissues and neurons with TRIzol reagent (Thermo Fisher, 15596026). Then 2 μg of total RNA was subjected to cDNA synthesis with the First Strand cDNA Synthesis Kit (Thermo Fisher, K1612). Next, the relative mRNA levels of targeted genes were analyzed by quantitative real-time PCR (qPCR) with iQ™ SYBR® Green Supermix (Bio-Rad, 1708880). The primers used for qPCR were as follows:

- **Bcat1 forward:** 5′-GAAGTGGCAGACTTTTAGG-3′
- **Bcat1 reverse:** 5′-TGTCGCTAAGTCTTCCA-3′
- **Bcat2 forward:** 5′-AAACATACAAAGTGAGACC-3′
- **Bcat2 reverse:** 5′-CTAGAGGCTGTTCCGTG-3′
- **Gapdh forward:** 5′-AATGGATTGGAGCATTGGT-3′
- **Gapdh reverse:** 5′-TTGCACGTGAGCTGTTGAT-3′

**Lentivirus packaging**

To knockdown the expression of mouse Bcat1, short-hairpin RNAs (shRNAs) targeting Bcat1 mRNA (shBcat1) were purchased from Invitrogen and expressed with lentivirus. The shRNA sequences targeting Bcat1 are as follows: shBcat1: 5′-GGGCAAAGATCTCATGATCA-3′. The lentivirus was prepared as described previously [20].

**Amyloid content measurement**

The accumulation of amyloid in the neurons was analyzed with the β-Amyloid (1-42) ELISA Kit (Invitrogen, 99-0064).

**Y-maze alternation task**

The total number of arm entries was recorded, as it was the number of entries representing alternation behavior (i.e. sequential entry into all three arms). All four paws of the mouse had to enter an arm for it to count as an arm entry. The percentage spontaneous alternation = (number of alternations)/(total arm entries − 2).

**Morris water maze**

The reference memory version of the MWM task was performed as described previously [1]. Briefly, animals were trained to swim in a 1.4 m diameter pool to find a submerged platform located 1 cm below the surface of water (24°C), rendered opaque by the addition of nontoxic white paint. Animals were pseudorandomly started from a different position at each trial and used distal visual spatial cues to find the hidden escape platform that remained in the center of the same quadrant throughout all training days. Training measures included escape latency to reach the platform and swim speed. To assess visual deficits and motivation to escape from water, the probe test was followed by a cued task during which the platform was visible. The visible platform was moved to different locations between each trial. After each trial, animals were immediately placed under a warming lamp to dry to prevent hypothermia.

**Statistical analysis**

The values are presented as the mean ± SEM of at least three independent repeats. Two-tail unpaired or paired Student’s *t*-test was applied to analyze the differences between two groups. Differences among groups were determined by one-way or two-way analysis of variance (ANOVA) with/without repeated measures, followed by the Bonferroni post-hoc test. *P* value of less than 0.05 was considered significant. All normalized data were normalized to the control group, which was considered as 1 or 100%. The statistical analyses were performed using GraphPad Prism 7.0.
Results

BCAAs accumulate in the serum of diabetic, aged, and AD patients and mice

BCAAs are associated with the development of diabetes [15]. We aimed to investigate whether BCAAs are a factor connecting diabetes and AD. The plasma levels of BCAAs in healthy donors and diabetic patients were determined. The results showed that BCAAs levels were increased in the serum of patients with type 2 diabetes (n=10; 6 males and 4 females; mean age = 69.1 years; 4 with and six without Alzheimer’s disease) compared with aged-matched healthy donors (n=6; 3 males and 3 females; mean age = 67.7 years; without AD) (Figure 1A). We also tested the plasma BCAA levels in wild-type mice and db/db mutant diabetic mice (4-month-old) and the results also showed that BCAA levels were increased in diabetic mice (Figure 1B). Next, we analyzed the plasma levels of BCAAs in AD patients (n=8; 5 males and 3 females; mean age = 71.3 years; 4 with and 4 without diabetes) compared with age-matched healthy donors (n=6; 3 males and 3 females; mean age = 69.7 years; without diabetes). The results revealed that the plasma BCAA levels were up-regulated in AD patients (Figure 1C). The up-regulation of BCAA levels in the plasma was also observed in the triple APPswet, PS1M146V, and TauP301L transgenic (3xTg) AD model compared with nontransgenic mice (Figure 1D). Aging is one of the core risk factors for diabetes and AD. Plasma levels of BCAAs were significantly up-regulated in aged donors (n=8; 5 males and 3 females; mean age = 76.3 years; 2 with diabetes and AD, 1 with diabetes and 1 with AD, and 4 without diabetes or AD) and mice (24-month-old) (Figure 1E,F). In addition, we also tested the level of lysine in the serum of the T2D, AD, and aged donors, not significant change in lysine serum level was observed (Supplementary Figure S1). Taken together, the up-regulation of BCAAs in the serum may connect diabetes and AD in human and mice.

BCAA diet increases cognitive deficits in 3xTg-AD mice

We next tested whether BCAAs supplement in the diet would affect the cognitive deficits in an AD mouse model. The 3xTg AD mice and nontransgenic wild-type mice were fed with a normal diet or BCAA diet for 3 months. We used the Y-maze to evaluate spatial working memory function in 3xTg-AD mice. Spontaneous alternations and total arm entries were calculated. There was no significant change in the arm entries in BCAAs-fed AD mice, indicating that the BCAAs did not affect general motor activity (Figure 2A). However, the spontaneous alternations indicated that the AD mice fed with BCAA diet made more incorrect choices compared with AD mice fed with normal diet (Figure 2B). Next, we also investigated whether BCAA diet reduced performance in the novel object recognition (NOR) task. Wild-type and AD mice had no significant differences in baseline locomotor activity as measured during the habituation phase. Interestingly, the discrimination index in the AD–BCAA group was significantly lower than those of the AD fed with normal diet (Figure 2C). Then we analyzed the effects of BCAA diet in the reference memory version of the Morris water maze (MWM). BCAA diet promoted the memory deficits in AD mice on day 4, 5, and 6 of the acquisition phase (Figure 2D). The longer escape latency of AD mice fed with BCAA diet was not attributed to slower swimming speed, as no significant difference was found between groups (Figure 2E). Collectively, our data revealed that BCAA diet increased cognitive deficits in AD mice, which indicates that BCAAs may connect diabetes and AD.

BCAT1 down-regulation activates the phosphorylation of Tau

BCAA accumulation may be affected by the branched-chain amino acid transaminase 1 (BCAT1) and BCAT2. Therefore, we analyzed the expression of Bcat1 and Bcat2 in the brain tissues of diabetic, aged, and AD mice. The results showed that the mRNA and protein levels of Bcat1 but not Bcat2 were significantly down-regulated in the brain tissues of diabetic, aged, and AD mice compared with their control mice (Figure 3A–D).

As one of the hallmarks of AD, extracellular accumulation of β-amyloid peptides has been a common target. We, therefore, analyzed whether Bcat1 down-regulation and subsequent accumulation of BCAAs in the brain tissues affect the content of β-amyloid peptides in the AD mice. The results showed that BCAA diet did not affect the content of β-amyloid peptides in the brain of AD mice (Figure 3E). Another hallmark of the AD is hyperphosphorylation and accumulation of the Tau protein, a microtubule-associated protein known to play a role in axonal growth and plasticity [1]. We found that BCAA diet significantly increased the phosphorylated level of Tau in the brain tissues of the AD mice (Figure 3F). Next, we also analyzed which amino acid affected the accumulation of phosphorylated Tau protein in isolated neurons. The results showed that leucine but not isoleucine or valine up-regulated the level of phosphorylated Tau protein in neurons isolated from 3xTg mice (Figure 3G). We also knocked down the expression of Bcat1 with lentivirus in isolated neurons of AD mice and found that Bcat1 knockdown up-regulated the levels of phosphorylated levels of Tau in neurons (Figure 3H).
Figure 1. BCAAs accumulate in the blood of human and mouse diabetes and Alzheimer’s disease

(A) BCAA levels were increased in the serum of diabetic patients (n=10; 6 males and 4 females; mean age = 69.1 years; 4 with and 6 without Alzheimer’s disease) compared with age-matched healthy donors (n=6; 3 males and 3 females; mean age = 67.7 years; without AD); T2D, type 2 diabetes. (B) BCAA levels were increased in the serum of db/db diabetic mice (leptin receptor mutant mice) compared with age-matched littermates (n=5). All the mice were males and 4 months old. (C) BCAA levels were increased in the serum of patients with AD (n=8; 5 males and 3 females; mean age = 71.3 years; 4 with and 4 without diabetes) compared with age-matched healthy donors (n=6; 3 males and 3 females; mean age = 69.7 years; without diabetes). (D) BCAA levels were increased in the serum of triple APP<sub>Swe</sub>, PS<sub>M146V</sub>, and Tau<sub>P301L</sub> transgenic (3xTg) AD mice compared with age-matched littermates (n=5). All the mice were males and 6 months old. (E) BCAA levels were increased in the serum of aged donors (n=8; 5 males and 3 females; mean age = 76.3 years; 2 with diabetes and 1 with AD and 4 without diabetes or AD) compared with young donors (n=6; 4 males and 2 females; mean age = 34.5 years; without diabetes or AD). (F) BCAA levels were increased in the serum of aged (24-month-old) male mice compared with young (4-month-old) male mice (n=5); *<i>P</i>< 0.05, **<i>P</i>< 0.01, and ***<i>P</i>< 0.001 by unpaired Student’s t-test.
BCAA activates p-Tau in an mTOR-dependent manner

Finally, we analyzed the potential mechanism underlying leucine and BCAT1 effects on the phosphorylated level of Tau in brain tissues and neurons of AD mice. mTOR was reported to phosphorylate Tau [21]. We tested whether BCAA diet increased the activation of mTOR signaling in the brain tissues of AD mice and found that BCAA diet increased the phosphorylation levels of mTOR and its downstream target S6K1 (Figure 4A). Leucine treatment or Bcat1 knockdown also promoted the activation of the mTOR–S6K1 signaling (Figure 4B,C). Finally, we analyzed whether the mTOR signaling was critically involved in the effects of leucine and Bcat1 on phosphorylation of Tau. Therefore, we treated the neurons isolated from the AD mice with mTOR inhibitor rapamycin. The results showed that rapamycin treatment blocked the leucine- or Bcat1 knockdown-mediated accumulation of phosphorylated Tau in neurons (Figure 4D,E). Therefore, BCAAs activated p-Tau in an mTOR-dependent manner.

Discussion

Metabolic diseases are often present for years before becoming clinically apparent. BCAAs have highly significant association with future diabetes [15] and are associated with improvement in insulin resistance with weight loss [22]. Elevations in the concentrations of circulating BCAAs are significantly associated with obesity in children, adolescents, and young adults, which may independently predict future insulin resistance [23,24]. BCAA metabolism is also associated with neurological disorders. Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy, which is associated with the defect in BCAA metabolism [25]. In addition, impaired BCAA transport at the blood–brain barrier is another cause of autism spectrum disorder [26].
Since diabetes is tightly related to the development of AD and BCAA, metabolism is associated with diabetes and neurological disorders as we studied the potential roles of BCAA in the AD. We first analyzed the plasma levels of BCAA in diabetic, aged, or AD individuals in human and mice. Results showed that plasma levels of BCAAs were significantly up-regulated in the diabetic, aged, or AD individuals. High levels of plasma BCAAs are reported to be associated with insulin resistance [12], which is considered as a fundamental linker between diabetes and AD [27]. These findings reveal that BCAAs may connect diabetes, aging, and AD.

To explore the effects of high BCAA levels on the cognitive deficits of AD mice, we fed the 3xTg AD mice with BCAA diet and analyzed the behavior performance or memory capacity of these mice. Compared with 3xTg AD mice fed a normal diet, the BCAAs-fed AD mice showed more serious memory defects as evidenced by decreased alternation, negative discrimination index, and longer escape latency in MWM test. However, BCAA supplement alone did not change the general behaviors of wild-type mice, indicating that high BCAAs alone may not be a driver of the AD. In addition, we only found that BCAAs changed in patients with diabetes and AD. We did not obtain any evidence that BCAAs were the core connecting factor between diabetes and AD. Further, studies are needed to elucidate whether BCAAs were critically involved in the pathological process of the diabetic AD.

In contrast with many other factors that may regulate the risk of the AD, BCAAs are particularly susceptible to dietary modulation. Protein-restricted, high-carbohydrate diets improve metabolic health in rodents. Decreasing dietary BCAAs has been shown to improve metabolic health in rodents. Feeding mice a diet specifically reduced in BCAAs is sufficient to improve glucose tolerance and body composition equivalently to a PR diet via metabolically distinct pathways [28]. BCAA restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing the efficiency of fatty acid oxidation and acyl-glyceride export [29]. A reduced BCAA diet promotes rapid fat mass loss without calorie restriction in obese mice. Selective reduction in dietary BCAAs also restores glucose tolerance and insulin sensitivity to obese mice, even as they continue to consume a high-fat, high-sugar diet [30]. In addition, plasma ileucine levels have been genetically linked with the risk of AD [31]. Our data also demonstrated the plasma BCAAs were increased in AD and BCAAs promoted the development of AD. Therefore, protein-restricted diet or BCAAs-restricted diet may serve as a potential approach for AD treatment.
BCAA supplement showed varying results in different conditions. Long-term supplement of BCAAs in the diet was reported to promote survival and support cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice [32]. However, others reported that BCAA supplement promoted heart failure and ischemic injury by impairing glucose metabolism and induce mitochondrial oxidative stress [18,33]. Therefore, further evidence is needed to elucidate the physiological and pathological functions of BCAAs in different tissues and conditions.

There are two aminotransferases for BCAAs; namely, BCAT1 in the cytosol and BCAT2 in the mitochondria [12]. We observed that BCAT1 but not BCAT2 was down-regulated in the brain tissues from diabetic, aged, or AD mice. Down-regulation of BCAT1 would result in the accumulation of BCAAs in cells the tissues, which is a core mechanism underlying several types of cancer, including leukemia [34], nonsmall cell lung cancer [13], pancreatic adenocarcinoma [35], and breast cancer [36]. For instance, BCAT1 exerts its oncogenic function through BCAA production of leukemia by activating mTOR signaling [35]. Indeed, we observed that BCAA supplement in the diet activated mTOR signaling in the brain tissues, which may be due to the effects of leucine, an activator for mTOR signaling. Importantly, we showed that BCAA supplement promotes phosphorylation of Tau protein in the brains of 3xTg AD mice, which was further confirmed in isolated neurons treated with leucine or BCAT1 knockdown. Our results showed that these effects of leucine and BCAT1 were largely dependent upon the activation of mTOR, which was previously reported to phosphorylate Tau protein directly [21]. However, BCAAs and BCAT1 did not change the content of β-amyloid peptides in the brain tissues of AD mice.

Figure 4. BCAAs promote the p-Tau in an mTOR-dependent manner
(A) Representative Western blot and quantitative results showing BCAA diet activated mTOR signaling in the brain tissues of 3xTg AD mice (n=4, *P<0.05, **P<0.01 by unpaired Student’s t-test). (B) Representative Western blot and quantitative results showing leucine activated mTOR signaling in the neurons isolated from mice. The neurons were isolated from the 3xTg AD mice and treated with leucine (1 mM) for 24 h. The experiments were repeated for three times. **P<0.01 by unpaired Student’s t-test. (C) Representative Western blot and quantitative results showing BCAT1 knockdown activated mTOR signaling in the neurons isolated from mice. The neurons were isolated from the 3xTg AD mice and infected with lentivirus carrying indicated shRNAs for 48 h. The experiments were repeated for three times. **P<0.01 by unpaired Student’s t-test. (D) Representative Western blot and quantitative results showing inhibition of mTOR with rapamycin repress leucine-mediated increase in phosphorylated Tau protein in neurons isolated from mice. The neurons were isolated from the 3xTg AD mice and treated with leucine (1 mM) and rapamycin (10 nM) for 24 h. The experiments were repeated for three times. **P<0.01 by one-way ANOVA followed by Bonferroni post-hoc test. (E) Representative Western blot and quantitative results showing inhibition of mTOR with rapamycin repress BCAT1 knockdown-mediated increase in phosphorylated Tau protein in neurons isolated from mice. The neurons were isolated from the 3xTg AD mice and infected with lentivirus carrying indicated shRNAs in the presence of rapamycin (10 nM) for 48 h. The experiments were repeated for three times. **P<0.01 by one-way ANOVA followed by Bonferroni post-hoc test.
In conclusion, our findings implicate that BCAAs may be one of the mechanisms connecting diabetes and AD. BCAA serum levels are increased in patients with diabetes and AD and supplement of BCAA in the diet promoted the development of AD by regulating the accumulation of phosphorylated Tau protein in an mTOR-dependent manner.

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Funding
We especially thank Dr Weiqiao Qiu and Haihao Zhu of Boston University, who technically supported this work, especially, on Aβ measurement. This research was in part supported by grants from the Department of Science and Technology of Chang Zhou [No. C20130839; Grant name: the Applied Basic Research Programs of Chang Zhou].

Author Contribution
Huajie Li designed the experiments, and obtained animal and molecular experiments data. Dan Ye collected blood samples and analyzed the BCAA levels. Wei Xie generated the shRNA targeting Bcat1. Fei Hua and Yilin Yang performed Western blot analysis. Jian Wu and Aifang Gu participated in the analysis of mRNA levels of target genes. Yi Ren and Keshi Mao participated in animal experiments and statistical analysis. Huajie Li wrote the manuscript and all authors have read the manuscript and confirmed the submission.

Abbreviations
AD, Alzheimer's disease; BCAA, branched-chain amino acid; BCAT1, branched-chain amino acid transaminase 1; IDE, insulin degrading enzyme; mTOR, mammalian target of rapamycin; MWM, Morris water maze; PR, protein-restricted; NOR, novel object recognition.

References
1 Scheltens, P., Blennow, K., Breteler, M.M., de Strooper, B., Frisoni, G.B., Salloway, S. et al. (2016) Alzheimer's disease. Lancet 388, 505–517, https://doi.org/10.1016/S0140-6736(15)01124-1
2 Canter, R.G., Penney, J. and Tsai, L.H. (2016) The road to restoring neural circuits for the treatment of Alzheimer's disease. Nature 539, 187–196, https://doi.org/10.1038/nature20412
3 Blennow, K., Mattsson, N., Schott, M., Hansson, O. and Zetterberg, H. (2015) Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol. Sci. 36, 297–309, https://doi.org/10.1016/j.tips.2015.03.002
4 de la Monte, S.M. and Tung, M. (2014) Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem. Pharmacol. 88, 548–559, https://doi.org/10.1016/j.bcp.2013.12.012
5 Pugazhenthi, S., Qin, L. and Reddy, P.H. (2017) Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease. Biochim. Biophys. Acta 1863, 1037–1045, https://doi.org/10.1016/j.bbadis.2016.04.017
6 Jayaraman, A. and Pike, C.J. (2014) Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions. Curr. Diab. Rep. 14, 476, https://doi.org/10.1007/s11892-014-0476-2
7 Kennedy, B.K. and Lamming, D.W. (2016) The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging. Cell Metab. 23, 990–1003, https://doi.org/10.1016/j.cmet.2016.05.009
8 Galvan, V. and Hart, M.J. (2016) Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease. Biochim. Biophys. Acta 1862, 992–1007, https://doi.org/10.1016/j.bbadis.2015.11.010
9 Li, H., Wu, J., Zhu, L., Sha, L., Yang, S., Wei, J. et al. (2018) Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD. Biosci. Rep. 38, BSR20170862, https://doi.org/10.1042/BSR20170862
10 Li, H., Yang, S., Wu, J., Ji, L., Zhu, L., Cao, L. et al. (2017) cAMP/PKA signaling pathway contributes to neuronal apoptosis via regulating IDE expression in a mixed model of type 2 diabetes and Alzheimer's disease. J. Cell. Biochem. 119, 1616–1626, https://doi.org/10.1002/jcb.26321
11 Li, H., Cao, L., Ren, Y., Jiang, Y., Xie, W. and Li, D. (2017) GLP-1 receptor regulates cell growth through regulating IDE expression level in Aβ1-42-treated PC12 cells. Biosci. Rep., https://doi.org/10.1042/BSR20171284
12 Lynch, C.J. and Adams, S.H. (2014) amino acids in metabolic signalling and insulin resistance. Nat. Rev. Endocrinol. 10, 723–736, https://doi.org/10.1038/nrendo.2014.171
13 Meyers, J.R., Torrence, M.E., Danai, L.V., Papagiannakopoulos, T., Davidson, S.M., Bauer, M.R. et al. (2016) Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 353, 1161–1165, https://doi.org/10.1126/science.aaf5171
14 Meyers, J.R., Wu, C., Clish, C.B., Kraft, P., Torrence, M.E., Fiske, B.P. et al. (2014) Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat. Med. 20, 1193–1198, https://doi.org/10.1038/nm.3686
15 Wang, T.J., Larson, M.G., Vasan, R.S., Cheng, S., Rhee, E.P., McCabe, E. et al. (2011) Metabolite profiles and the risk of developing diabetes. Nat. Med. 17, 448–453, https://doi.org/10.1038/nm.2307
16 Jang, C., Oh, S.F., Wada, S., Rowe, G.C., Liu, L., Chan, M.C. et al. (2016) A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat. Med. 22, 421–426, https://doi.org/10.1038/nm.4057

© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
17 Ruiz-Canela, M., Toledo, E., Clish, C.B., Hruby, A., Liang, L., Salas-Salvado, J. et al. (2016) Plasma branched-chain amino acids and incident cardiovascular disease in the PREMID MED trial. Clin. Chem. 62, 582–592, https://doi.org/10.1373/clinchem.2015.251710
18 Sun, H., Olson, K.C., Gao, C., Prosdocimo, D.A., Zhou, M., Wang, Z. et al. (2016) Catabolic defect of branched-chain amino acids promotes heart failure. Circulation 133, 2038–2049, https://doi.org/10.1161/CIRCULATIONAHA.115.020226
19 Pedersen, H.K., Gudmundsdottir, V., Nielsen, H.B., Høyblad, T., Nielsen, T., Jensen, B.A. et al. (2016) Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535, 376–381, https://doi.org/10.1038/nature18646
20 Ying, T.-H., Lee, C.-H., Chiou, H.-L., Yang, S.-F., Lin, C.-L., Hung, C.-H. et al. (2016) Knockdown of Pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells. Sci. Rep. 6, 29385, https://doi.org/10.1038/srep29385
21 Caccamo, A., Majumder, S., Richardson, A., Strong, R. and Oddo, S. (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-β, and tau effects on cognitive impairments. J. Biol. Chem. 285, 13107–13120, https://doi.org/10.1074/jbc.M110.100420
22 Shah, S.H., Crosslin, D.R., Haynes, C.S., Nelson, S., Turer, C.B., Stevens, R.D. et al. (2012) Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia 55, 321–330, https://doi.org/10.1007/s00125-011-2356-5
23 Würtz, P., Soininen, P., Kangas, A.J., Rönemaa, T., Kähönen, M. et al. (2013) Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care 36, 648–655, https://doi.org/10.23736/dc12-0895
24 McCormack, S.E., Shaham, O., McCarthy, M.A., Deik, O., Wang, T.J., Gerszten, R.E. et al. (2013) Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. Pediatr. Obes. 8, 52–61, https://doi.org/10.1111/j.2047-6310.2012.00087.x
25 Novarino, G., El-Fishawy, P., Kayserilli, H., Meguid, N.A., Scott, E.M., Schroth, J. et al. (2012) Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science 338, 394–397, https://doi.org/10.1126/science.1224631
26 Tarlungeanu, D.C., Deliu, E., Dotter, C.P., Kara, M., Janiesch, P.C., Scalise, M. et al. (2016) Impaired amino acid transport at the blood brain barrier is a cause of autism spectrum disorder. Cell 167, 1481–1494, e1418, https://doi.org/10.1016/j.cell.2016.11.013
27 Yarchoan, M. and Arnold, S.E. (2014) Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 63, 2253–2261, https://doi.org/10.2337/db13-0287
28 Fontana, L., Cummings, N.E., Arriola Apelo, S.J., Neuman, J.C., Kasza, I., Schmidt, B.A. et al. (2016) Decreased consumption of branched-chain amino acids improves metabolic health. Cell Rep. 16, 520–530, https://doi.org/10.1016/j.celrep.2016.05.092
29 White, P.J., Lapworth, A.L., An, J., Wang, L., McInnes, I.B., Kayserilli, H., Meguid, N.A., Scott, E.M., Schroth, J. et al. (2012) Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia 55, 321–330, https://doi.org/10.1007/s00125-011-2356-5
30 Cummings, N.E., Williams, E.M., Kasza, I., Konon, E.N., Schaich, M.D., Schmidt, B.A. et al. (2018) Restoration of metabolic health by decreased consumption of branched-chain amino acids. J. Physiol. 596, 623–645, https://doi.org/10.1113/jp275075
31 Larsson, S.C. and Markus, H.S. (2017) Branched-chain amino acids and Alzheimer’s disease: a Mendelian randomization analysis. Sci. Rep. 7, 13604, https://doi.org/10.1038/s41598-017-12931-1
32 D’Antona, G., Ragini, M., Cardile, A., Tedesco, L., Dossena, M., Bruttini, F. et al. (2010) Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice. Cell Metab. 12, 362–372, https://doi.org/10.1016/j.cmet.2010.08.016
33 Li, T., Zhang, Z., Kolwicz, J.C., Abell, L., Roe, N.D., Kim, M. et al. (2017) Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion injury. Cell Metab. 25, 374–385, https://doi.org/10.1016/j.cmet.2016.11.005
34 Hattori, A., Tsunoda, M., Konuma, T., Kobayashi, M., Nagy, T., Glushka, J. et al. (2017) Cancer progression by reprogrammed BCAA metabolism in myeloid leukemias. Nature 545, 500–504, https://doi.org/10.1038/nature22314
35 Dey, P., Baddour, J., Muller, F., Wu, C.C., Wang, H., Liao, W.T. et al. (2017) Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature 542, 119–123, https://doi.org/10.1038/nature21052
36 Thewes, V., Simon, R., Hviid, M., Schlotter, M., Schroeter, F., Schmidt, K. et al. (2017) The branched-chain amino acid transaminase 1 sustains growth of antileukemic-resistant and ERalpha-negative breast cancer. Oncogene 36, 4124–4134, https://doi.org/10.1038/onc.2017.32